NewsBenzinga웨드부시, 페이트 테라퓨틱스에 대한 ‘시장수익률 상회’ 의견 재확인···목표주가 7달러 유지 웨드부시, 페이트 테라퓨틱스에 대한 ‘시장수익률 상회’ 의견 재확인···목표주가 7달러 유지 Benzinga 2026.10.27 13:17 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report